Thiolated chitosans:: Development and in vitro evaluation of an oral tobramycin sulphate delivery system

被引:46
作者
Hombach, Juliane [1 ]
Hoyer, Herbert [1 ]
Bernkop-Schnuerch, Andreas [1 ]
机构
[1] Leopold Franzens Univ Innsbruck, Inst Pharm, A-6020 Innsbruck, Austria
关键词
tobramycin sulphate; permeation enhancement; Caco-2; cells; ussing-type chambers; chitosan-NAC;
D O I
10.1016/j.ejps.2007.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the present study was to develop and evaluate an oral delivery system for tobramycin sulphate intended to improve the oral bioavailability Chitosan was thiolated by the immobilisation of N-acetylcysteine (NAC) to the amino groups of the polymer. The permeation enhancing effect of the resulting chitosan-NAC conjugate in combination with the permeation mediator glutathione (GSH) was evaluated both in Ussing-type chambers across freshly excised rat intestinal mucosa and Caco-2 cells using the poorly orally absorbed aminoglycoside tobramycin sulphate as model drug. Additionally, the release profile from tablets containing tobramycin sulphate, chitosan-NAC and glutathione was determined. The obtained thiomer chitosan-NAC displayed 962.2 +/- 53.2 mu mol thiol groups per gram polymer of which 35.5 +/- 5.0% were oxidised. In comparison to buffer only, tobramycin sulphate uptake in presence of 0.5% (w/v) unmodified chitosan, 0.5% (w/v) chitosan-NAC, 0.5% (w/v) glutathione and the combination of 0.5% (w/v) glutathione and 0.5% (w/v) chitosan-NAC was improved 1.2-fold, 1.3-fold, 1.5-fold and 2.0-fold, respectively, across rat small intestine and 2.6-fold, 2.7-fold, 1.6-fold and 3.3-fold, respectively, across Caco-2 cell monolayer. Almost 90% of the tobramycin sulphate was released from tablets within 4h. The developed drug delivery system containing chitosan-NAC and glutathione is a promising tool for oral tobramycin sulphate administration showing improved gastrointestinal uptake and a sustained release. (c) 2007 Published by Elsevier B.V.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 34 条
[1]   The treatment of respiratory pseudomonas infection in cystic fibrosis - What drug and which way? [J].
Banerjee, D ;
Stableforth, D .
DRUGS, 2000, 60 (05) :1053-1064
[2]   Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein [J].
Banerjee, SK ;
Jagannath, C ;
Hunter, RL ;
Dasgupta, A .
LIFE SCIENCES, 2000, 67 (16) :2011-2016
[3]   Regulation of PTP1B via glutathionylation of the active site cysteine 215 [J].
Barrett, WC ;
DeGnore, JP ;
König, S ;
Fales, HM ;
Keng, YF ;
Zhang, ZY ;
Yim, MB ;
Chock, PB .
BIOCHEMISTRY, 1999, 38 (20) :6699-6705
[4]  
Bemkop-Schnurch A, 1999, SCI PHARM, V67, P196
[5]   The use of thiolated polymers as carrier matrix in oral peptide delivery -: Proof of concept [J].
Bernkop-Schnürch, A ;
Pinter, Y ;
Guggi, D ;
Kahlbacher, H ;
Schöffmann, G ;
Schuh, M ;
Schmerold, I ;
Del Curto, MD ;
D'Antonio, M ;
Esposito, P ;
Huck, C .
JOURNAL OF CONTROLLED RELEASE, 2005, 106 (1-2) :26-33
[6]   Permeation enhancing polymers in oral delivery of hydrophilic macromolecules:: thiomer/GSH systems [J].
Bernkop-Schnürch, A ;
Kast, CE ;
Guggi, D .
JOURNAL OF CONTROLLED RELEASE, 2003, 93 (02) :95-103
[7]   Thiolated polymers-thiomers:: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates [J].
Bernkop-Schnürch, A ;
Hornof, M ;
Zoidl, T .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 260 (02) :229-237
[8]  
Bernkop-Schnurch A., 2001, Scientia Pharmazeutica, V69, P109, DOI DOI 10.3797/SCIPHARM.AUT-01-12
[9]   Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin [J].
Cavalli, R ;
Bargon, A ;
Podio, V ;
Munton, E ;
Zara, CP ;
Gasco, MR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (05) :1085-1094
[10]   The role of glutathione in the permeation enhancing effect of thiolated polymers [J].
Clausen, AE ;
Kast, CE ;
Bernkop-Schnürch, A .
PHARMACEUTICAL RESEARCH, 2002, 19 (05) :602-608